As scrutiny mounts on China-based pharmaceutical companies like WuXi AppTec over alleged government ties, India’s contract development and manufacturing organization (CDMO) sector stands poised to capitalize on the opportunity. Congressional pressure has intensified on WuXi and other Chinese firms, raising concerns about potential security risks and data privacy issues.
This shift in focus could lead to increased interest in India’s growing CDMO industry, which offers a robust alternative for global pharmaceutical companies seeking reliable partners. With its skilled workforce, competitive costs, and strong intellectual property protection, India’s CDMOs are well-positioned to attract new business from clients looking to diversify their supply chains and mitigate geopolitical risks.
